Maze Therapeutics (NASDAQ:MAZE) Sees Large Volume Increase – Should You Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE) saw unusually-strong trading volume on Friday . 583,220 shares were traded during mid-day trading, a decline of 8% from the previous session’s volume of 634,280 shares.The stock last traded at $24.7240 and had previously closed at $24.82.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. BTIG Research reaffirmed a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $66.00.

Maze Therapeutics Trading Down 0.7%

The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The stock has a market cap of $1.37 billion, a P/E ratio of -9.73 and a beta of 2.17. The stock has a 50-day moving average price of $28.33 and a 200-day moving average price of $30.50.

Maze Therapeutics (NASDAQ:MAZE) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, hitting the consensus estimate of ($0.76). On average, equities research analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Insider Transactions at Maze Therapeutics

In other news, insider Atul Dandekar sold 7,500 shares of the firm’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $27.58, for a total transaction of $206,850.00. Following the sale, the insider owned 26,250 shares in the company, valued at approximately $723,975. This trade represents a 22.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason Coloma sold 34,501 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total transaction of $907,031.29. Following the sale, the chief executive officer owned 18,151 shares in the company, valued at approximately $477,189.79. This trade represents a 65.53% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 219,317 shares of company stock valued at $5,989,040 in the last quarter. Insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC boosted its holdings in shares of Maze Therapeutics by 42.8% in the 2nd quarter. Squarepoint Ops LLC now owns 19,434 shares of the company’s stock worth $580,000 after purchasing an additional 5,822 shares in the last quarter. California State Teachers Retirement System raised its holdings in shares of Maze Therapeutics by 54,096.5% during the 2nd quarter. California State Teachers Retirement System now owns 777,720 shares of the company’s stock valued at $23,207,000 after buying an additional 776,285 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its position in Maze Therapeutics by 10.2% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after buying an additional 465,641 shares during the last quarter. AXQ Capital LP lifted its position in Maze Therapeutics by 114.1% in the 2nd quarter. AXQ Capital LP now owns 15,193 shares of the company’s stock worth $453,000 after buying an additional 8,098 shares during the last quarter. Finally, Braidwell LP purchased a new stake in Maze Therapeutics in the second quarter worth approximately $34,019,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.